An AAV-Based, Room-Temperature Stable, Single Dose COVID-19 Vaccine
bioRxiv preprint doi: https://doi.org/10.1101/2021.01.05.422952; this version posted January 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. An AAV-based, room-temperature stable, single dose COVID-19 vaccine Nerea Zabaleta1,2,3,4, Wenlong Dai1,2,3,4, Urja Bhatt1,2,3,4, Jessica A Chichester5, Julio Sanmiguel1,2,3,4, Reynette Estelien1,2,3,4, Kristofer T Michalson5, Cheikh Diop1,2,3,4, Dawid Maciorowski1,2,3,4, Wenbin Qi6, Elissa Hudspeth7, Allison Cucalon1,2,3,4, Cecilia D Dyer5, M. Betina Pampena5,8, James J. Knox9, Regina C LaRocque10,11, Richelle C Charles10,11, Dan Li1,2,3,4, Maya Kim1,2,3,4, Abigail Sheridan1,2,3,4, Nadia Storm12, Rebecca I Johnson12, Jared Feldman13, Blake M Hauser13, Aisling Ryan1,2,3,4, Eric Zinn1,2,3,4, Dione T Kobayashi14, Ruchi Chauhan1,2,3,4, Marion McGlynn5, Edward T Ryan10,11,15, Aaron G Schmidt13,16, Brian Price17, Anna Honko12, Anthony Griffiths12, Sam Yaghmour6, Robert Hodge18, Michael R. Betts5,8, Mason W Freeman19, James M Wilson5, Luk H Vandenberghe1,2,3,4,* 1 Grousbeck Gene Therapy Center, Schepens Eye Research Institute, Mass Eye and Ear, Boston, Massachusetts, USA 2 Ocular Genomics Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA 3 The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA 4 Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA 5Gene Therapy Program, Perelman School of Medicine, University
[Show full text]